Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic…
Roche announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto (pralsetinib) for the treatment of adult and paediatric patients 12 years of age and older with…
Read More...
Read More...
